Close



Mar 28, 2024 08:31AM
Mar 28, 2024 08:30AM
Mar 6, 2024 10:25AM
Mar 6, 2024 10:25AM
Mar 5, 2024 04:31PM
Mar 5, 2024 04:30PM
Mar 5, 2024 07:03AM RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Mar 5, 2024 07:00AM
Feb 26, 2024 04:07PM
Feb 26, 2024 04:05PM
Feb 26, 2024 08:33AM
Feb 26, 2024 08:30AM
Feb 20, 2024 07:00AM
Feb 12, 2024 08:55AM Gilead Sciences (GILD) to acquire CymaBay Therapeutics (CBAY) in $4.3bn cash deal
Feb 12, 2024 08:42AM
Feb 12, 2024 08:32AM
Feb 12, 2024 08:30AM
Feb 6, 2024 04:02PM
Jan 30, 2024 08:31AM
Jan 30, 2024 08:30AM
Dec 21, 2023 04:05PM U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data
Dec 21, 2023 07:01AM
Dec 20, 2023 08:45AM
Dec 19, 2023 07:01AM
Dec 19, 2023 07:00AM
Dec 12, 2023 03:22AM
Dec 11, 2023 07:30PM
Nov 15, 2023 06:00AM Kite (GILD) and Arcellx (ACLX) Expand Strategic Partnership
Nov 15, 2023 06:00AM
Nov 15, 2023 06:00AM
Nov 7, 2023 04:02PM
Nov 3, 2023 11:00AM
Nov 2, 2023 09:15AM
Oct 12, 2023 09:00AM
Oct 3, 2023 08:30AM Gilead to Present Latest Innovative Virology Data on Current and Potentially Transformative Therapies Across HIV and COVID-19 at IDWeek 2023
Aug 24, 2023 08:30AM
Aug 24, 2023 08:30AM
Aug 21, 2023 02:22PM
Aug 21, 2023 08:30AM
Aug 21, 2023 08:30AM
Aug 8, 2023 04:01PM
Aug 3, 2023 04:02PM Gilead Sciences Announces Second Quarter 2023 Financial Results
Jul 23, 2023 09:51PM
Jul 19, 2023 08:30AM
Jul 14, 2023 08:03AM
Jul 14, 2023 08:00AM
Jun 23, 2023 02:30AM
Jun 14, 2023 03:00AM
Jun 6, 2023 10:47AM Gilead's(GILD) Kite's Tecartus CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate
Jun 6, 2023 10:45AM

251,622 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All